Global Evkeeza Market Forecast: Key Growth Drivers, Trends, and Opportunities from 2025 to 2034

January 25, 2025 04:09 AM AEDT | By EIN Presswire
 Global Evkeeza Market Forecast: Key Growth Drivers, Trends, and Opportunities from 2025 to 2034
Image source: EIN Presswire

LANDON, GREATER LANDON, UNITED KINGDOM, January 24, 2025 /EINPresswire.com/ -- Unveiling the 2025 Market Reports: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the historical progress and projected growth of the Evkeeza market?
The Evkeeza market size has been growing at a significant pace in recent years. The market value, which stood at $XX million in 2024, is expected to catapult to $XX million in 2025, with a compound annual growth rate CAGR of XX%. The appreciable growth in the historic period can be credited to supportive regulations and policies, rapid advances in genomics and personalized medicine, an aging population, favorable government policies, and the emergence of situations like birth defects.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20070&type=smp

How is the Evkeeza market expected to evolve in the future?
Projections for the Evkeeza market are promising, as it is expected to accelerate at a forward compound annual growth rate CAGR of XX% over the next years. It is anticipated to inflate to $XX million by 2029, largely driven by the rising prevalence of hypercholesterolemia, the increasing occurrence of rare diseases worldwide, the growing burden of rare neurological diseases and escalating healthcare expenditure. A plethora of trends anticipated to shape the forecast period include the development of specialized medications, the advent of personalized medicine, telemedicine and remote monitoring, patient support program expansions, and regulatory approvals.

What are the significant market drivers in the Evkeeza industry?
A pivotal growth driver in the Evkeeza market is the increasing prevalence of genetic disorders, expected to fuel the market's expansion. Genetic disorders, sourced from abnormalities in an individual's DNA, are induced by mutations in one or more genes or changes in the number of chromosomes. The uptick in genetic disorders, boosted by upgraded diagnostic technologies and escalating environmental factors contributing to genetic conditions, is driving the demand for Evkeeza. The drug is leveraged to treat homozygous familial hypercholesterolemia HoFH, a genetic disorder that leads to high LDL cholesterol levels, by inhibiting ANGPTL3. With projections from the American Society of Hematology predicting the global population of individuals suffering from sickle cell disease SCD to grow by roughly 30% by 2050, the exacerbating genetic disorders are indeed fueling the Evkeeza market's growth.

Who are the leading players in the Evkeeza market?
Key players in the Evkeeza market include the notable Regeneron Pharmaceuticals Inc., contributing significantly to the market growth.

What are the emerging trends in the Evkeeza market?
Major trends heralding in the Evkeeza market involve regulatory approvals for drugs to bolster their reach and fortify their foothold in treating patients with homozygous familial hypercholesterolemia HoFH. A case in point is the FDA approval awarded to Regeneron Pharmaceuticals Inc. in March 2023. The approval was for an ANGPTL3 inhibitor, Evkeeza evinacumab-dgnb, marking it as the first to be granted for a demographic of young children aged between 5 to 11 years suffering from HoFH. It emerges as a new treatment option for nearly 1,300 affected individuals in the U.S., offering an average LDL-C level reduction of 48% after 24 weeks of treatment alongside other lipid-lowering therapies.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/evkeeza-global-market-report

How is the Evkeeza market segmented?
The Evkeeza market is segmented by Indication into Primary Hypercholesterolemia, Homozygous Familial Hypercholesterolemia; by Route Of Administration into Intravenous IV Infusion, Self-Administration, Subcutaneous SC Administration, Hospital Infusion Centers, Infusion In Ambulatory Care Settings; and by Distribution Channel into Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies.

Which regions dominate the Evkeeza market?
Interestingly, North America triumphed as the largest market share holder in the Evkeeza market in 2024, though Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Evkeeza market report span across Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and, Africa.

Browse for more similar reports-
Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/vascular-endothelial-growth-factor-inhibitors-global-market-report

Pharmaceutical API Manufacturing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pharmaceutical-api-manufacturing-global-market-report

Alpha Mannosidosis Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report

Dive into similar comprehensive reports by The Business Research Company.

Equipped with over 15000+ reports across 27 industries that cover 60+ geographies, The Business Research Company is dedicated to providing comprehensive, data-rich research and insights. With 1,500,000 datasets, exhaustive secondary research techniques, and unique inputs from industry leaders, we deliver the information you need to stay ahead of the curve.

For more information, contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
Facebook
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.